Conflicts of interest and disclosure in the American Psychiatric Association's clinical practice guidelines

Psychotherapy and Psychosomatics

Volumn 78, Issue 4, 2009, Pages 228-232

  Cosgrove, Lisa ^a   Bursztajn, Harold J ^b   Krimsky, Sheldon ^c   Anaya, Maria ^a   Walker, Justin ^a  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Clinical practice guidelines; Conflict of interest; Financial associations

Indexed keywords

ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; CONFLICT OF INTEREST; DRUG INDUSTRY; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE PERSONNEL; INTERPERSONAL COMMUNICATION; MAJOR DEPRESSION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRY; SCHIZOPHRENIA; SCREENING;

AUTHORSHIP; BIPOLAR DISORDER; CONFLICT OF INTEREST; DEPRESSIVE DISORDER, MAJOR; DISCLOSURE; DRUG INDUSTRY; ETHICS, MEDICAL; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRY; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SOCIETIES, MEDICAL; UNITED STATES;

EID: 65449176486     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214444     Document Type: Article

References (31)

1. Choudhry NK, Stelfox HT, Detsky AS: Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-617.
2. Genuis S: The proliferation of clinical practice guidelines: professional development or medicine-by-numbers? J Am Board Fam Prac 2005;18:419-425.
3. Grilli R, Magrini N, Penna A, Giorgio M, Liberati A: Practice guidelines developed by specialty societies: the need for critical appraisal. Lancet 2000;355:103-106.
4. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL: Association of funding and conclusions in randomized drug trials. JAMA 2003;290:921-928.
5. Fava GA: Financial conflicts of interest in psychiatry. World Psychiatry 2007;6:19-24.
6. Carey B, Harris G: Psychiatric association faces Senate scrutiny over drug industry ties. New York Times, July 12, 2008, p A13.
7. Bass A: Side Effects. Chapel Hill, Algonquin Books, 2008.
8. www.forensic-psych.com (accessed August 21, 2008).
9. Herelin A: What is the impact of financial conflicts of interest on the development of psychiatry? World Psychiatry 2007;6:36-37.
10. Fava GA: The intellectual crisis of psychiatric research. Psychother Psychosom 2006;75:202-208.
11. Starcvic V: Opportunistic 'rediscovery' of mental disorders by the pharmaceutical industry. Psychother Psychosom 2001;71:305-310.
12. Vieta E: Psychiatry: from interest in conf licts to conflicts of interest. World Psychiatry 2007;6:27-29.
13. Bursztajn HJ, Feinbloom RI, Hamm RM, Brodsky A: Medical Choices, Medical Chances: How Patients, Families, and Physicians Can Cope with Uncertainty. New York, Delacorte Press/Seymour Lawrence, 1981; New York, Routledge, 1990.
14. Cosgrove L, Krimsky S, Vijayraghavan M, Schneider L: Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 2006;75:154-160.
15. American Psychiatric Association: APA names DSM-V task force members: leading experts to revise handbook for diagnosing mental disorders (press release). Washington, APA, July 232007.
16. APA: Meet the work groups. www.psych.org/MainMenu/Research/DSMIV/DSMV/ WorkGroups.aspx (accessed June 20, 2008).
17. National Institute of Mental Health: The numbers count: mental disorders in America. http://www.nimh.nih.gov/health/publications/the-numbers-count- mental-disorders-in-america/index.shtml (accessed August 20, 2008).
18. Moreno C, Laje G, Blanco C, Jiang H, Schmidt A, Olfson M: National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatr 2007;64:1032-1039.
19. IMS: 2007 top therapeutic classes of drugs by US sales. www.imshealth.com (accessed August 21, 2008).
20. Cosgrove L, Bursztajn HJ: Towards credible conflict of interest policies in psychiatry. Psychiatr Times 2009;26:40-41.
21. Stelfox HT, Chua G, O'Rourke K, Detsky AS: Conflict of interest in the debate over calcium channel antagonists. N Engl J Med 1998;338:101-106.
22. Krimsky S: Science in the Private Interest. Lanham, Rowman & Littlefield, 2003.
23. Angell M: The Truth about Drug Companies: How They Deceive Us and What to Do about It. New York, Random House, 2004.
24. Avorn J: Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med 2006;355:2169-2171.
25. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG: Empirical evidence for selective reporting of outcomes in randomized trials. JA MA 2004;291:2457-2465.
26. Balon R: By whom and how is the quality of research data collection assured and checked? Psychother Psychosom 2005;74:331-335.
27. Cialdini RB: Influence: The Psychology of Persuasion. New York, Quill William Morrow, 1993.
28. Katz D, Mertz J, Caplan A: All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift giving. Am J Bioethics 2003;3:39-46.
29. Wazanza A: Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-380.
30. Bitton A, Neuman MD, Barnoya J, Glantz SA: The p53 tumour suppressor gene and the tobacco industry: research debate, and conflict of interest. Lancet 2005;365:531-340.
31. Cosgrove L, Bursztajn HJ: Undoing undue industry influence: lessons from psychiatry as psychopharmacology. J Org Ethics 2006;3:131-133.